ASCO 2024 | Fertility-preserving hormonal therapy in early-stage endometrial cancer

Yukio Suzuki • 1 Jun 2024

ASCO 2024

Yukio Suzuki, MD, PhD, Columbia University Irving Medical Center, New York, NY, explores the safety and long-term outcomes of progesterone-based therapy for fertility preservation in young women with early-stage endometrial cancer. The study found that 5-year survival was slightly lower with hormonal therapy compared to hysterectomy, especially in women aged 40-49, where hormonal therapy was linked to increased mortality risk. These findings underscore the need for careful patient selection for hormonal therapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.